Cyclosporine A loaded electrospun poly(D,L-lactic acid)/poly(ethylene glycol) nanofibers: drug carriers utilizable in local immunosuppression

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389013%3A_____%2F17%3A00474919" target="_blank" >RIV/61389013:_____/17:00474919 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/68378041:_____/17:00474919 RIV/00216208:11310/17:10362593

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s11095-017-2155-x" target="_blank" >http://dx.doi.org/10.1007/s11095-017-2155-x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s11095-017-2155-x" target="_blank" >10.1007/s11095-017-2155-x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cyclosporine A loaded electrospun poly(D,L-lactic acid)/poly(ethylene glycol) nanofibers: drug carriers utilizable in local immunosuppression

Popis výsledku v původním jazyce

The present study aims to prepare poly(D,L-lactic acid) (PLA) nanofibers loaded by the immunosuppressant cyclosporine A (CsA, 10 wt%). Amphiphilic poly(ethylene glycol)s (PEG) additives were used to modify the hydrophobic drug release kinetics. Four types of CsA-loaded PLA nanofibrous carriers varying in the presence and molecular weight (MW) of PEG (6, 20 and 35 kDa) were prepared by needleless electrospinning. The samples were extracted for 144 h in phosphate buffer saline or tissue culture medium. A newly developed and validated LC-MS/MS method was utilized to quantify the amount of released CsA from the carriers. In vitro cell experiments were used to evaluate biological activity. Nanofibers containing 15 wt% of PEG showed improved drug release characteristics. Significantly higher release rates were achieved in initial part of experiment (24 h). The highest released doses of CsA were obtained from the nanofibers with PEG of the lowest MW (6 kDa). In vitro experiments on ConA-stimulated spleen cells revealed the biological activity of the released CsA for the whole study period of 144 h and nanofibers containing PEG with the lowest MW exhibited the highest impact (inhibition). The addition of PEG of a particular MW enables to control CsA release from PLA nanofibrous carriers. The biological activity of CsA-loaded PLA nanofibers with PEG persists even after 144 h of previous extraction. Prepared materials are promising for local immunosuppression in various medical applications.

Název v anglickém jazyce

Cyclosporine A loaded electrospun poly(D,L-lactic acid)/poly(ethylene glycol) nanofibers: drug carriers utilizable in local immunosuppression

Popis výsledku anglicky

The present study aims to prepare poly(D,L-lactic acid) (PLA) nanofibers loaded by the immunosuppressant cyclosporine A (CsA, 10 wt%). Amphiphilic poly(ethylene glycol)s (PEG) additives were used to modify the hydrophobic drug release kinetics. Four types of CsA-loaded PLA nanofibrous carriers varying in the presence and molecular weight (MW) of PEG (6, 20 and 35 kDa) were prepared by needleless electrospinning. The samples were extracted for 144 h in phosphate buffer saline or tissue culture medium. A newly developed and validated LC-MS/MS method was utilized to quantify the amount of released CsA from the carriers. In vitro cell experiments were used to evaluate biological activity. Nanofibers containing 15 wt% of PEG showed improved drug release characteristics. Significantly higher release rates were achieved in initial part of experiment (24 h). The highest released doses of CsA were obtained from the nanofibers with PEG of the lowest MW (6 kDa). In vitro experiments on ConA-stimulated spleen cells revealed the biological activity of the released CsA for the whole study period of 144 h and nanofibers containing PEG with the lowest MW exhibited the highest impact (inhibition). The addition of PEG of a particular MW enables to control CsA release from PLA nanofibrous carriers. The biological activity of CsA-loaded PLA nanofibers with PEG persists even after 144 h of previous extraction. Prepared materials are promising for local immunosuppression in various medical applications.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10609 - Biochemical research methods

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pharmaceutical Research

ISSN

0724-8741

e-ISSN

—

Svazek periodika

34

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

1391-1401

Kód UT WoS článku

000402193300004

EID výsledku v databázi Scopus

2-s2.0-85017551870